Microarray Expression Analysis for the Paradoxical Roles of Acanthopanax senticosus Harms in Treating α-Synucleinopathies
Xu-zhao Li
Chinese Medicine Toxicological Laboratory, Heilongjiang University of Chinese Medicine, Harbin, 150040 China
Department of Pharmacy, GuiYang College of Traditional Chinese Medicine, GuiYang, 550025 China
Joint first authors.Search for more papers by this authorShuai-nan Zhang
Chinese Medicine Toxicological Laboratory, Heilongjiang University of Chinese Medicine, Harbin, 150040 China
Joint first authors.Search for more papers by this authorCorresponding Author
Fang Lu
Chinese Medicine Toxicological Laboratory, Heilongjiang University of Chinese Medicine, Harbin, 150040 China
Correspondence to: Shu-min Liu, Drug Safety Evaluation Center, Heilongjiang University of Chinese Medicine, He Ping Road 24, Harbin 150040, China; Fang Lu, Chinese Medicine Toxicological Laboratory, Heilongjiang University of Chinese Medicine, He Ping Road 24, Harbin 150040, China.
E-mail: [email protected] (Shu-min Liu); [email protected] (Fang Lu)
Search for more papers by this authorCorresponding Author
Shu-min Liu
Chinese Medicine Toxicological Laboratory, Heilongjiang University of Chinese Medicine, Harbin, 150040 China
Drug Safety Evaluation Center, Heilongjiang University of Chinese Medicine, Harbin, 150040 China
Correspondence to: Shu-min Liu, Drug Safety Evaluation Center, Heilongjiang University of Chinese Medicine, He Ping Road 24, Harbin 150040, China; Fang Lu, Chinese Medicine Toxicological Laboratory, Heilongjiang University of Chinese Medicine, He Ping Road 24, Harbin 150040, China.
E-mail: [email protected] (Shu-min Liu); [email protected] (Fang Lu)
Search for more papers by this authorXu-zhao Li
Chinese Medicine Toxicological Laboratory, Heilongjiang University of Chinese Medicine, Harbin, 150040 China
Department of Pharmacy, GuiYang College of Traditional Chinese Medicine, GuiYang, 550025 China
Joint first authors.Search for more papers by this authorShuai-nan Zhang
Chinese Medicine Toxicological Laboratory, Heilongjiang University of Chinese Medicine, Harbin, 150040 China
Joint first authors.Search for more papers by this authorCorresponding Author
Fang Lu
Chinese Medicine Toxicological Laboratory, Heilongjiang University of Chinese Medicine, Harbin, 150040 China
Correspondence to: Shu-min Liu, Drug Safety Evaluation Center, Heilongjiang University of Chinese Medicine, He Ping Road 24, Harbin 150040, China; Fang Lu, Chinese Medicine Toxicological Laboratory, Heilongjiang University of Chinese Medicine, He Ping Road 24, Harbin 150040, China.
E-mail: [email protected] (Shu-min Liu); [email protected] (Fang Lu)
Search for more papers by this authorCorresponding Author
Shu-min Liu
Chinese Medicine Toxicological Laboratory, Heilongjiang University of Chinese Medicine, Harbin, 150040 China
Drug Safety Evaluation Center, Heilongjiang University of Chinese Medicine, Harbin, 150040 China
Correspondence to: Shu-min Liu, Drug Safety Evaluation Center, Heilongjiang University of Chinese Medicine, He Ping Road 24, Harbin 150040, China; Fang Lu, Chinese Medicine Toxicological Laboratory, Heilongjiang University of Chinese Medicine, He Ping Road 24, Harbin 150040, China.
E-mail: [email protected] (Shu-min Liu); [email protected] (Fang Lu)
Search for more papers by this authorAbstract
α-Synuclein is a key player in the pathogenesis of neurodegenerative disorders with Lewy bodies. Our previous studies have also showed that Acanthopanax senticosus harms (AS) could significantly suppress α-synuclein overexpression and toxicity. Identifying the RNAs related to α-synucleinopathies may facilitate understanding the pathogenesis of the diseases and the safe application of AS in the clinic. Microarray expression profiling of long non-coding RNAs (lncRNAs) and mRNAs was undertaken in control non-transgenic and human α-synuclein transgenic mice. The effects of AS on central nervous system (CNS) in pathology and physiology were investigated based on the lncRNA/mRNA targets analysis. In total, 341 lncRNAs and 279 mRNAs were differentially expressed by α-synuclein stimulus, among which 29 lncRNAs and 25 mRNAs were involved in the anti-α-synucleinopathies mechanism of AS. However, the levels of 19/29 lncRNAs and 12/25 mRNAs in AS group were similar to those in α-synuclein group, which may cause potential neurotoxicity analogous to α-synuclein. This study demonstrated that some of lncRNAs/mRNAs were involved in α-synuclein related pathophysiology, and AS produced the bidirectional effects on CNS under pathological and physiological conditions. Copyright © 2015 John Wiley & Sons, Ltd.
Supporting Information
| Filename | Description |
|---|---|
| ptr5522-sup-0001-supplementary.zipapplication/x-zip-compressed, 265.4 KB | Supporting info item |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- Alvarez-Bolado G, Zhou X, Voss AK, et al. 2000. Winged helix transcription factor Foxb1 is essential for access of mammillothalamic axons to the thalamus. Development 127: 1029–1038.
- Amsen EM, Pham N, Pak Y, et al. 2006. The guanine nucleotide exchange factor CNrasGEF regulates melanogenesis and cell survival in melanoma cells. J Biol Chem 281: 121–128.
- Baba M, Nakajo S, Tu PH, et al. 1998. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol 152: 879–884.
- Bai L, Xu H, Collins JF, et al. 2001. Molecular and functional analysis of a novel neuronal vesicular glutamate transporter. J Biol Chem 276: 36764–36769.
- Banerjee K, Sinha M, Pham Cle L, et al. 2010. Alpha-synuclein induced membrane depolarization and loss of phosphorylation capacity of isolated rat brain mitochondria: implications in Parkinson's disease. FEBS Lett 584: 1571–1576.
- Bouligand J, Ghervan C, Trabado S, et al. 2010. Genetics defects in GNRH1: a paradigm of hypothalamic congenital gonadotropin deficiency. Brain Res 1364: 3–9.
- Bourque M, Dluzen DE, Di Paolo T. 2009. Neuroprotective actions of sex steroids in Parkinson's disease. Front Neuroendocrinol 30: 142–157.
- Brinkmeier ML, Potok MA, Davis SW, et al. 2007. TCF4 deficiency expands ventral diencephalon signaling and increases induction of pituitary progenitors. Dev Biol 311: 396–407.
- Camandola S, Mattson MP. 2007. NF-kappa B as a therapeutic target in neurodegenerative diseases. Expert Opin Ther Targets 11: 123–132.
- Chapman MA. 2014. Interactions between cell adhesion and the synaptic vesicle cycle in Parkinson's disease. Med Hypotheses 83: 203–207.
- Chen GH, McDonald RA, Wells JC, et al. 2005. The gamma interferon receptor is required for the protective pulmonary inflammatory response to Cryptococcus neoformans. Infect Immun 73: 1788–1796.
- Chen XD, Tang FQ, Sun H. 2009. Signal pathway in sinusitis, polyps and normal nasal mucosa through bioinformatics analysis on differentially expressed-proteins. Biomedical Engineering and Informatics, 2009, BMEI'09. 2nd International Conference on. IEEE, pp. 1–4.
- ChPC. 2010. Radix et, Rhizoma seu Caulis Acanthopanacis Senticosi (Ciwaujia). In Pharmacopoeia of the People's Republic of China 1. China Medical Science Press: Beijing, China; 192.
- Damas JK, Smith C, Oie E, et al. 2007. Enhanced expression of the homeostatic chemokines CCL19 and CCL21 in clinical and experimental atherosclerosis: possible pathogenic role in plaque destabilization. Arterioscler Thromb Vasc Biol 27: 614–620.
- Diao Y, Guo X, Li Y, et al. 2012. Pax3/7BP is a Pax7- and Pax3-binding protein that regulates the proliferation of muscle precursor cells by an epigenetic mechanism. Cell Stem Cell 11: 231–241.
- Epstein DJ, Vekemans M, Gros P. 1991. Splotch (Sp2H), a mutation affecting development of the mouse neural tube, shows a deletion within the paired homeodomain of Pax-3. Cell 67: 767–774.
- Eriksen JL, Dawson TM, Dickson DW, et al. 2003. Caught in the act: alpha-synuclein is the culprit in Parkinson's disease. Neuron 40: 453–456.
- Garcia-Fresco GP, Sousa AD, Pillai AM, et al. 2006. Disruption of axo-glial junctions causes cytoskeletal disorganization and degeneration of Purkinje neuron axons. Proc Natl Acad Sci U S A 103: 5137–5142.
- Huang Y, Zhou X, Miao B, et al. 2009. An image based system biology approach for Alzheimer's disease pathway analysis. IEEE NIH Life Sci Syst Appl Workshop 2009: 128–132.
- Huang LZ, Huang BK, Ye Q, et al. 2011. Bioactivity-guided fractionation for anti-fatigue property of Acanthopanax senticosus. J Ethnopharmacol 133: 213–219.
- Jetten MJ, Ruiz-Aracama A, Coonen ML, et al. 2015. Interindividual variation in gene expression responses and metabolite formation in acetaminophen-exposed primary human hepatocytes. Arch Toxicol . DOI:10.1007/s00204-00015-01545-00202.
- Jobin C, Bradham CA, Russo MP, et al. 1999. Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. J Immunol 163: 3474–3483.
- Junn E, Ronchetti RD, Quezado MM, et al. 2003. Tissue transglutaminase-induced aggregation of alpha-synuclein: implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A 100: 2047–2052.
- Kang W, Liu J, Chen S. 2012. 3.033 The aggregated WT-α-synuclein and A53T promote inflammation through activation of NADPH oxidase complex in BV-2 and primary microglia. Parkinsonism Relat Disord 18: S177.
- Kao SY. 2009. Rescue of alpha-synuclein cytotoxicity by insulin-like growth factors. Biochem Biophys Res Commun 385: 434–438.
- Kim HG, Oh MS. 2012. Herbal medicines for the prevention and treatment of Alzheimer's disease. Curr Pharm Des 18: 57–75.
- Lau A, Tymianski M. 2010. Glutamate receptors, neurotoxicity and neurodegeneration. Pflugers Arch 460: 525–542.
- Lawrence T, Gilroy DW, Colville-Nash PR, et al. 2001. Possible new role for NF-kappaB in the resolution of inflammation. Nat Med 7: 1291–1297.
- Lee D, Park J, Yoon J, et al. 2012. Neuroprotective effects of Eleutherococcus senticosus bark on transient global cerebral ischemia in rats. J Ethnopharmacol 139: 6–11.
- Li XZ, Zhang SN, Liu SM, et al. 2013a. Recent advances in herbal medicines treating Parkinson's disease. Fitoterapia 84: 273–285.
- Li XZ, Zhang SN, Lu F, et al. 2013b. Cerebral metabonomics study on Parkinson's disease mice treated with extract of Acanthopanax senticosus harms. Phytomedicine 20: 1219–1229.
- Li XZ, Zhang SN, Wang KX, et al. 2014a. Neuroprotective effects of extract of Acanthopanax senticosus harms on SH-SY5Y cells overexpressing wild-type or A53T mutant α-synuclein. Phytomedicine 21: 704–711.
- Li XZ, Zhang SN, Wang KX, et al. 2014b. iTRAQ-based quantitative proteomics study on the neuroprotective effects of extract of Acanthopanax senticosus harm on SH-SY5Y cells overexpressing A53T mutant alpha-synuclein. Neurochem Int 72: 37–47.
- Ling KH, Hewitt CA, Beissbarth T, et al. 2011. Spatiotemporal regulation of multiple overlapping sense and novel natural antisense transcripts at the Nrgn and Camk2n1 gene loci during mouse cerebral corticogenesis. Cereb Cortex 21: 683–697.
- Liu SM, Li XZ, Huo Y, et al. 2012. Protective effect of extract of Acanthopanax senticosus Harms on dopaminergic neurons in Parkinson's disease mice. Phytomedicine 19: 631–638.
- Lortet S, Lacombe E, Boulanger N, et al. 2013. Striatal molecular signature of subchronic subthalamic nucleus high frequency stimulation in parkinsonian rat. PLoS One 8e60447: 1–14.
- Masliah E, Rockenstein E, Veinbergs I, et al. 2000. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287: 1265–1269.
- Mathy NL, Scheuer W, Lanzendorfer M, et al. 2000. Interleukin-16 stimulates the expression and production of pro-inflammatory cytokines by human monocytes. Immunology 100: 63–69.
- Melachroinou K, Xilouri M, Emmanouilidou E, et al. 2013. Deregulation of calcium homeostasis mediates secreted alpha-synuclein-induced neurotoxicity. Neurobiol Aging 34: 2853–2865.
- Mercer TR, Neph S, Dinger ME, et al. 2011. The human mitochondrial transcriptome. Cell 146: 645–658.
- Miguelez C, Morera-Herreras T, Torrecilla M, et al. 2014. Interaction between the 5-HT system and the basal ganglia: functional implication and therapeutic perspective in Parkinson's disease. Front Neural Circuit 8: 1–9.
- Mila S, Albo AG, Corpillo D, et al. 2009. Lymphocyte proteomics of Parkinson's disease patients reveals cytoskeletal protein dysregulation and oxidative stress. Biomark Med 3: 117–128.
- Musgrove RE, King AE, Dickson TC. 2013. alpha-Synuclein protects neurons from apoptosis downstream of free-radical production through modulation of the MAPK signalling pathway. Neurotox Res 23: 358–369.
- Ng SY, Lin L, Soh BS, et al. 2013. Long noncoding RNAs in development and disease of the central nervous system. Trends Genet 29: 461–468.
- Noguchi-Shinohara M, Tokuda T, Yoshita M, et al. 2009. CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer's disease. Brain Res 1251: 1–6.
- Ogata M, Inanami O, Nakajima M, et al. 2003. Ca(2+)-dependent and caspase-3-independent apoptosis caused by damage in Golgi apparatus due to 2,4,5,7-tetrabromorhodamine 123 bromide-induced photodynamic effects. Photochem Photobiol 78: 241–247.
- Qureshi IA, Mattick JS, Mehler MF. 2010. Long non-coding RNAs in nervous system function and disease. Brain Res 1338: 20–35.
- Rackham O, Shearwood AM, Mercer TR, et al. 2011. Long noncoding RNAs are generated from the mitochondrial genome and regulated by nuclear-encoded proteins. RNA 17: 2085–2093.
- Rodriguez-Gabin AG, Yin X, Si Q, et al. 2009. Transport of mannose-6-phosphate receptors from the trans-Golgi network to endosomes requires Rab31. Exp Cell Res 315: 2215–2230.
- Schapira AH. 2012. Mitochondrial diseases. Lancet 379: 1825–1834.
- Simon HH, Saueressig H, Wurst W, et al. 2001. Fate of midbrain dopaminergic neurons controlled by the engrailed genes. J Neurosci 21: 3126–3134.
- Sironi C, Teesalu T, Muggia A, et al. 2009. EFA6A encodes two isoforms with distinct biological activities in neuronal cells. J Cell Sci 122: 2108–2118.
- Song JX, Sze SC, Ng TB, et al. 2012. Anti-Parkinsonian drug discovery from herbal medicines: what have we got from neurotoxic models? J Ethnopharmacol 139: 698–711.
- Spillantini MG, Crowther RA, Jakes R, et al. 1998. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A 95: 6469–6473.
- Stefanova N, Reindl M, Neumann M, et al. 2005. Oxidative stress in transgenic mice with oligodendroglial alpha-synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy. Am J Pathol 166: 869–876.
- Tofaris GK, Layfield R, Spillantini MG. 2001. Alpha-synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome. FEBS Lett 509: 22–26.
- Tofaris GK, Garcia Reitbock P, Humby T, et al. 2006. Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120): implications for Lewy body disorders. J Neurosci 26: 3942–3950.
- Van der Zee CE, Hagg T. 1998. p75NGFR mediates death of cholinergic neurons during postnatal development of the neostriatum in mice. J Chem Neuroanat 14: 129–140.
- Wahl C, Muller W, Leithauser F, et al. 2009. IL-20 receptor 2 signaling down-regulates antigen-specific T cell responses. J Immunol 182: 802–810.
- Wakamatsu M, Iwata S, Funakoshi T, et al. 2008. Dopamine receptor agonists reverse behavioral abnormalities of alpha-synuclein transgenic mouse, a new model of Parkinson's disease. J Neurosci Res 86: 640–646.
- Wang JB, Zhao HP, Zhao YL, et al. 2011. Hepatotoxicity or hepatoprotection? Pattern recognition for the paradoxical effect of the Chinese herb Rheum palmatum L. in treating rat liver injury. PLoS One 6e24498: 1–8.
- Watts JC, Giles K, Oehler A, et al. 2013. Transmission of multiple system atrophy prions to transgenic mice. Proc Natl Acad Sci U S A 110: 19555–19560.
- Wei W, Pelechano V, Jarvelin AI, et al. 2011. Functional consequences of bidirectional promoters. Trends Genet 27: 267–276.
- WHO. 2004. Radix Eleutherococci. In WHO Monographs on Selected Medicinal Plants 2. WHO: Geneva; 83–96.
- Winklhofer KF, Haass C. 2010. Mitochondrial dysfunction in Parkinson's disease. Biochim Biophys Acta 1802: 29–44.
- Wu F, Li H, Zhao L, et al. 2013. Protective effects of aqueous extract from Acanthopanax senticosus against corticosterone-induced neurotoxicity in PC12 cells. J Ethnopharmacol 148: 861–868.
- Xu Y, Han C, Xu S, et al. 2008. Effects of Acanthopanax senticosus on learning and memory in a mouse model of Alzheimer's disease and protection against free radical injury to brain tissue. Neural Regen Res 3: 192–195.
- Yamano M, Ogura H, Okuyama S, et al. 2002. Modulation of 5-HT system in mice with a targeted disruption of neuromedin B receptor. J Neurosci Res 68: 59–64.
- Yan MH, Wang X, Zhu X. 2013. Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease. Free Radic Biol Med 62: 90–101.
- Yang Y, Li H, Hou S, et al. 2013. The noncoding RNA expression profile and the effect of lncRNA AK126698 on cisplatin resistance in non-small-cell lung cancer cell. PLoS One 8e65309: 1–12.
10.1371/journal.pone.0074916 Google Scholar
- Zhang SN, Li XZ, Wang Y, et al. 2014. Neuroprotection or neurotoxicity? New insights into the effects of Acanthopanax senticosus harms on nervous system through cerebral metabolomics analysis. J Ethnopharmacol 156: 290–300.
- Zhang SN, Li XZ, Lu F, et al. 2015. Cerebral potential biomarkers discovery and metabolic pathways analysis of α-synucleinopathies and the dual effects of Acanthopanax senticosus Harms on central nervous system through metabolomics analysis. J Ethnopharmacol 163: 264–272.
- Zhou ZD, Yap BP, Gung AY, et al. 2006. Dopamine-related and caspase-independent apoptosis in dopaminergic neurons induced by overexpression of human wild type or mutant alpha-synuclein. Exp Cell Res 312: 156–170.
Citing Literature
